NBY - NovaBay Pharmaceuticals, Inc.
NYSE
->
Healthcare
->
Biotechnology
EmeryVille,
United States
Type: Equity
NBY price evolution
NBY
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.55 | $0.73 | $0.76 | $0.92 |
| Inventory | $0.7 | $0.66 | $2.88 | $3.49 |
| Total current assets | $2.25 | $3.59 | $7.15 | $8.21 |
| Long term investments | ||||
| Property, plant & equipment | $1.2 | $1.29 | $1.38 | $1.62 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $3.92 | $5.36 | $9.03 | $12.85 |
| Current liabilities | ||||
| Accounts payable | $1.24 | $1.12 | $1.13 | $0.95 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.61 | $3.92 | $4.28 | $4.57 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4.54 | $5.2 | $5.72 | $5.82 |
| Shareholders' equity | ||||
| Retained earnings | -$180.03 | -$178.44 | -$174.85 | -$165.68 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.95 | |||
| Short term investments | ||||
| Net receivables | $0.76 | $1.97 | $1.67 | $1.11 |
| Inventory | $2.88 | $3.44 | $3.22 | $0.61 |
| Total current assets | $7.15 | $11.33 | $13.17 | $14.24 |
| Long term investments | ||||
| Property, plant & equipment | $1.38 | $1.95 | $0.6 | $0.08 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1 | |||
| Total investments | ||||
| Total assets | $9.03 | $16.4 | $23.98 | $15.24 |
| Current liabilities | ||||
| Accounts payable | $1.13 | $1.08 | $1.04 | $0.3 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $4.28 | $4.26 | $3.44 | $2.83 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.09 | |||
| Total debt | ||||
| Total liabilities | $5.72 | $5.84 | $13.81 | $2.92 |
| Shareholders' equity | ||||
| Retained earnings | -$174.85 | -$158.15 | -$141.89 | -$136.06 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.04 | $2.63 | ||
| Cost of revenue | ||||
| Gross Profit | $1.55 | $1.52 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $3.7 | $3.9 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $2.27 | |||
| Net income | ||||
| Net income | -$2.15 | -$0.11 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.93 | $6.6 | $12.51 | |
| Cost of revenue | ||||
| Gross Profit | $5.96 | $4.86 | $11.01 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $13.36 | $15 | $19.38 | |
| Operating income | -$6.43 | -$9.4 | -$7.87 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.01 | -$0.01 | -$0 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$11.03 | -$9.65 | -$6.54 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.11 | -$0.03 | -$0.02 | -$12.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.6 | -$0.1 | -$0.1 | $16.79 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.96 | -$3.89 | -$2.18 | -$4.44 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Net income | -$11.04 | -$9.66 | -$6.54 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$4.72 | -$7.93 | -$5.57 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$12.04 | -$0.03 | -$0.02 | -$0.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $16.79 | $9.76 | $11.7 | $5.6 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4.44 | $5.01 | $3.75 | -$0.01 |
News
Fundamentals
| Market cap | $835.76K |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 1.35M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.62 |
| Quick ratio | 0.43 |